Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

The con­di­tion­al mar­ket­ing au­tho­riza­tion for Ad­vanz Phar­ma’s liv­er dis­ease treat­ment Ocali­va has been re­voked fol­low­ing a de­ci­sion by the Gen­er­al Court of the Eu­ro­pean Union …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER